Lexicon pharmaceuticals, inc.LXRX.US Overview

US StockHealthcare

(No presentation for LXRX)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

LXRX Overall Performance

LXRX AI Analysis & Strategy

LXRX Recent Performance

1.63%

Lexicon pharmaceuticals, inc.

0.81%

Avg of Sector

-1.14%

S&P500

LXRX PowerScanner

LXRX Key Information

LXRX Valuation Metrics

LXRX Earnings Table

LXRX Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.